
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
OPKO Health, Inc is a diagnostics & research business with stocks listed in the US. OPKO Health shares (OPK) are listed on the NASDAQ and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$1.1171 - US$6.47 |
---|---|
50-day moving average | US$5.0436 |
200-day moving average | US$4.2574 |
Target price | US$8.25 |
PE ratio | 96.25 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$0.048 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing OPKO Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of OPKO Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
OPKO Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 96x. In other words, OPKO Health shares trade at around 96x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
OPKO Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$139.1 million (£0.0 million).
The EBITDA is a measure of a OPKO Health's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | US$1.4 billion |
---|---|
Operating margin TTM | 3.74% |
Gross profit TTM | US$541 million |
Return on assets TTM | 1.4% |
Return on equity TTM | 1.86% |
Profit margin | 2.13% |
Book value | 2.495 |
Market capitalisation | US$3.1 billion |
TTM: trailing 12 months
There are currently 97.4 million OPKO Health shares held short by investors – that's known as OPKO Health's "short interest". This figure is 5% down from 102.5 million last month.
There are a few different ways that this level of interest in shorting OPKO Health shares can be evaluated.
OPKO Health's "short interest ratio" (SIR) is the quantity of OPKO Health shares currently shorted divided by the average quantity of OPKO Health shares traded daily (recently around 9.1 million). OPKO Health's SIR currently stands at 10.76. In other words for every 100,000 OPKO Health shares traded daily on the market, roughly 10760 shares are currently held short.
However OPKO Health's short interest can also be evaluated against the total number of OPKO Health shares, or, against the total number of tradable OPKO Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OPKO Health's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 OPKO Health shares in existence, roughly 150 shares are currently held short) or 0.2432% of the tradable shares (for every 100,000 tradable OPKO Health shares, roughly 243 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against OPKO Health.
Find out more about how you can short OPKO Health stock.
We're not expecting OPKO Health to pay a dividend over the next 12 months.
Over the last 12 months, OPKO Health's shares have ranged in value from as little as US$1.1171 up to US$6.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OPKO Health's is 1.8762. This would suggest that OPKO Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Steps to owning and managing Liberty Financial Group shares.
Steps to owning and managing Cettire shares.
Steps to owning and managing BHP Group shares.
Steps to owning and managing Fisher & Paykel Healthcare Corp Ltd shares.
From Membership Rewards Points to savings on first and business class flights, this charge card is packed with features to help you manage business spending.
From the best sheets for summer to the most luxurious threads, these are the 7 best bed sheets you can get in Australia right now.
Everything we know about the Bumble IPO, plus information on how to buy in.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Superhero IPO, plus information on how to buy in.
Everything we know about the Kuaishou IPO, plus information on how to buy in.